RYALTRIS®

About Glenmark

Glenmark Pharmaceuticals has evolved from its 1977 origins as an Indian generics manufacturer into a global, publicly traded biopharmaceutical enterprise with a strategic U.S. headquarters. The company operates on a hybrid model, combining the stable revenue base of a generics business with targeted R&D investments in novel Respiratory, Dermatology, and Oncology therapies. This strategy is supported by significant global infrastructure, including 11 manufacturing facilities and 6 R&D centers, aiming to deliver both innovative treatments and broad accessibility to patients in over 80 countries.

Therapeutic Areas

Other Allergic Rhinitis Drugs